Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
AT

NASDAQ · ATHA

Athira Pharma, Inc.

Healthcare · Biotechnology

$6.75

Down-$0.44 (-6.12%)

Updated Aug 15, 2026, 5:13 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
26.62M
P/E ratio
-0.59
Dividend yield
0.00%
52-week range
$0.22 – $8.36
Volume
70.31K
Avg. volume
1.06M

Price performance

ATHA price history

1M range · 0 trading sessions · Daily adjusted prices

ATHA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ATHA news

The latest Smart Investors Daily articles mentioning ATHA.

Stock researchCompany · Overview

ATHA research

Overview

Company profile and research snapshot.

Company profile

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
ATHA recent ratings
DateFirmRatingTarget
Sep 19, 2024MizuhoNeutral—
Sep 4, 2024JMP SecuritiesMarket Perform—
Sep 4, 2024BTIGNeutral—
Aug 19, 2024Rodman & RenshawBuy—
Jun 20, 2024JMP SecuritiesMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

thenewswire.com · Dec 11, 2025

Generation Uranium Applauds ATHA Energy's Uranium Discoverys In The Angikuni Basin, South Of Generations YATH Project

Vancouver, British Columbia – December 11, 2025 – TheNewswire - Generation Uranium Inc. (TSXV:GEN, OTCQB: GENRF) (the “Company” or “Generation”) is pleased to see Atha Energy's success in exploration in the Angikuni Basin located south of the Companies Yath Project. Atha has now reported multiple discoveries at the RIB target area on November 20 th and December 10, 2025. All exploration drill holes at the RIB zone intersected uranium mineralization, (Atha press release, Dec 10, 2025) with up to 5.55% U3O8. These discoveries are a clear demonstration of both the Angikuni Basin's uranium potential and also the hard work and effective exploration of the Atha Energy team.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By